Drugs / Oral hexavalent reassortant rotavirus attenuated live vaccine
Oral hexavalent reassortant rotavirus attenuated live vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06950645 | Mar → Dec 2024 | Rotavirus infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral hexavalent reassortant rotavirus attenuated live vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06950645 ↗ |
| Modality | Vaccine | “oral hexavalent reassortant rotavirus attenuated live vaccine” NCT06950645 ↗ |
| Route | Oral | “administered orally” NCT06950645 ↗ |